Compare Novavax Inc (NVAX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Wells Fargo & Co — how do they compare? Novavax Inc trades at $7.97 (market cap $1.31B), while Wells Fargo & Co trades at $87.3 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 202× Novavax Inc's market cap, and Wells Fargo & Co pays a 2.29% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | WFC | |
|---|---|---|
Market Cap | $1.31B | $264.66B |
Sector | Health | Financials |
52-Week High | $11.19 | $96.40 |
52-Week Low | $6.22 | $73.42 |
Enterprise Value | $889.30M | — |
Dividend Yield | — | 2.29% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
